Dr. Kolberg on the LILAC Study of ABP 980 in Breast Cancer
August 12th 2019
Hans-Christian Kolberg, MD, head, Department of Obstetrics and Gynecology, Breast Cancer Center, and Gynecologic Cancer Center at Marienhospital Bottrop, Klinik für Gynäkologie und Geburtshilfe, Bottrop, Germany, discusses the phase III LILAC study, which examined ABP 980 (Kanjinti; trastuzumab-anns), a trastuzumab (Herceptin) biosimilar, in early-stage HER2-positive breast cancer.